Hypocalcaemia in patients with metastatic bone disease treated with denosumab.
Identifieur interne : 002962 ( PubMed/Corpus ); précédent : 002961; suivant : 002963Hypocalcaemia in patients with metastatic bone disease treated with denosumab.
Auteurs : Jean-Jacques Body ; Henry G. Bone ; Richard H. De Boer ; Alison Stopeck ; Catherine Van Poznak ; Ronaldo Damião ; Karim Fizazi ; David H. Henry ; Toni Ibrahim ; Allan Lipton ; Fred Saad ; Neal Shore ; Toshimi Takano ; Adam J. Shaywitz ; Huei Wang ; Oswaldo L. Bracco ; Ada Braun ; Paul J. KostenuikSource :
- European journal of cancer (Oxford, England : 1990) [ 1879-0852 ] ; 2015.
English descriptors
- KwdEn :
- Antineoplastic Agents (adverse effects), Biomarkers (blood), Bone Density Conservation Agents (adverse effects), Bone Neoplasms (drug therapy), Bone Neoplasms (secondary), Calcium (blood), Clinical Trials, Phase III as Topic, Denosumab (adverse effects), Diphosphonates (adverse effects), Humans, Hypocalcemia (blood), Hypocalcemia (chemically induced), Hypocalcemia (diagnosis), Hypocalcemia (epidemiology), Hypocalcemia (prevention & control), Imidazoles (adverse effects), Incidence, Retrospective Studies, Risk Assessment, Risk Factors, Severity of Illness Index, Time Factors, Treatment Outcome, Vitamin D Deficiency (complications), Vitamin D Deficiency (diagnosis).
- MESH :
- chemical , adverse effects : Antineoplastic Agents, Bone Density Conservation Agents, Denosumab, Diphosphonates, Imidazoles.
- chemical , blood : Biomarkers, Calcium.
- blood : Hypocalcemia.
- chemically induced : Hypocalcemia.
- complications : Vitamin D Deficiency.
- diagnosis : Hypocalcemia, Vitamin D Deficiency.
- drug therapy : Bone Neoplasms.
- epidemiology : Hypocalcemia.
- prevention & control : Hypocalcemia.
- secondary : Bone Neoplasms.
- Clinical Trials, Phase III as Topic, Humans, Incidence, Retrospective Studies, Risk Assessment, Risk Factors, Severity of Illness Index, Time Factors, Treatment Outcome.
Abstract
This analysis was performed to further characterise treatment-emergent hypocalcaemia in patients with bone metastases receiving denosumab.
DOI: 10.1016/j.ejca.2015.05.016
PubMed: 26093811
Links to Exploration step
pubmed:26093811Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Hypocalcaemia in patients with metastatic bone disease treated with denosumab.</title><author><name sortKey="Body, Jean Jacques" sort="Body, Jean Jacques" uniqKey="Body J" first="Jean-Jacques" last="Body">Jean-Jacques Body</name><affiliation><nlm:affiliation>Department of Medicine, CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium. Electronic address: jean-jacques.body@chu-brugmann.be.</nlm:affiliation></affiliation></author><author><name sortKey="Bone, Henry G" sort="Bone, Henry G" uniqKey="Bone H" first="Henry G" last="Bone">Henry G. Bone</name><affiliation><nlm:affiliation>Michigan Bone and Mineral Clinic, Detroit, MI, USA. Electronic address: hgbone.md@att.net.</nlm:affiliation></affiliation></author><author><name sortKey="De Boer, Richard H" sort="De Boer, Richard H" uniqKey="De Boer R" first="Richard H" last="De Boer">Richard H. De Boer</name><affiliation><nlm:affiliation>Department of Medical Oncology, Royal Melbourne Hospital, Melbourne, VIC, Australia. Electronic address: richard.deboer@wh.org.au.</nlm:affiliation></affiliation></author><author><name sortKey="Stopeck, Alison" sort="Stopeck, Alison" uniqKey="Stopeck A" first="Alison" last="Stopeck">Alison Stopeck</name><affiliation><nlm:affiliation>Stony Brook Cancer Center, Stony Brook, NY, USA. Electronic address: Alison.Stopeck@stonybrookmedicine.edu.</nlm:affiliation></affiliation></author><author><name sortKey="Van Poznak, Catherine" sort="Van Poznak, Catherine" uniqKey="Van Poznak C" first="Catherine" last="Van Poznak">Catherine Van Poznak</name><affiliation><nlm:affiliation>Department of Medical Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA. Electronic address: cvanpoz@med.umich.edu.</nlm:affiliation></affiliation></author><author><name sortKey="Damiao, Ronaldo" sort="Damiao, Ronaldo" uniqKey="Damiao R" first="Ronaldo" last="Damião">Ronaldo Damião</name><affiliation><nlm:affiliation>Department of Urology, Hospital Universitario Pedro Ernesto, Rio de Janeiro, Brazil. Electronic address: damiao@email.com.</nlm:affiliation></affiliation></author><author><name sortKey="Fizazi, Karim" sort="Fizazi, Karim" uniqKey="Fizazi K" first="Karim" last="Fizazi">Karim Fizazi</name><affiliation><nlm:affiliation>Department of Medical Oncology, Institut Gustave Roussy, University of Paris Sud, Villejuif, France. Electronic address: Karim.FIZAZI@igr.fr.</nlm:affiliation></affiliation></author><author><name sortKey="Henry, David H" sort="Henry, David H" uniqKey="Henry D" first="David H" last="Henry">David H. Henry</name><affiliation><nlm:affiliation>Department of Medicine, Joan Karnell Cancer Center at Pennsylvania Hospital, Philadelphia, PA, USA. Electronic address: dhhenry@juno.com.</nlm:affiliation></affiliation></author><author><name sortKey="Ibrahim, Toni" sort="Ibrahim, Toni" uniqKey="Ibrahim T" first="Toni" last="Ibrahim">Toni Ibrahim</name><affiliation><nlm:affiliation>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS-Osteoncology and Rare Tumors Center, Meldola, Italy. Electronic address: toni.ibrahim@irst.emr.it.</nlm:affiliation></affiliation></author><author><name sortKey="Lipton, Allan" sort="Lipton, Allan" uniqKey="Lipton A" first="Allan" last="Lipton">Allan Lipton</name><affiliation><nlm:affiliation>Division of Oncology, Pennsylvania State University, Milton S. Hershey Medical Center, Hershey, PA, USA. Electronic address: alipton@hmc.psu.edu.</nlm:affiliation></affiliation></author><author><name sortKey="Saad, Fred" sort="Saad, Fred" uniqKey="Saad F" first="Fred" last="Saad">Fred Saad</name><affiliation><nlm:affiliation>Department of Surgery, University of Montreal Hospital Center, Montreal, QC, Canada. Electronic address: fredsaad@videotron.ca.</nlm:affiliation></affiliation></author><author><name sortKey="Shore, Neal" sort="Shore, Neal" uniqKey="Shore N" first="Neal" last="Shore">Neal Shore</name><affiliation><nlm:affiliation>Department of Urology, Carolina Urologic Research Center, Myrtle Beach, SC, USA. Electronic address: nshore@gsuro.com.</nlm:affiliation></affiliation></author><author><name sortKey="Takano, Toshimi" sort="Takano, Toshimi" uniqKey="Takano T" first="Toshimi" last="Takano">Toshimi Takano</name><affiliation><nlm:affiliation>Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan. Electronic address: takano@toranomon.gr.jp.</nlm:affiliation></affiliation></author><author><name sortKey="Shaywitz, Adam J" sort="Shaywitz, Adam J" uniqKey="Shaywitz A" first="Adam J" last="Shaywitz">Adam J. Shaywitz</name><affiliation><nlm:affiliation>Department of Hematology/Oncology, Amgen Inc., Thousand Oaks, CA, USA. Electronic address: ashaywitz@gmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Wang, Huei" sort="Wang, Huei" uniqKey="Wang H" first="Huei" last="Wang">Huei Wang</name><affiliation><nlm:affiliation>Department of Hematology/Oncology, Amgen Inc., Thousand Oaks, CA, USA. Electronic address: hueiw@amgen.com.</nlm:affiliation></affiliation></author><author><name sortKey="Bracco, Oswaldo L" sort="Bracco, Oswaldo L" uniqKey="Bracco O" first="Oswaldo L" last="Bracco">Oswaldo L. Bracco</name><affiliation><nlm:affiliation>Department of Hematology/Oncology, Amgen Inc., Thousand Oaks, CA, USA. Electronic address: ozzie.bracco@gmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Braun, Ada" sort="Braun, Ada" uniqKey="Braun A" first="Ada" last="Braun">Ada Braun</name><affiliation><nlm:affiliation>Department of Hematology/Oncology, Amgen Inc., Thousand Oaks, CA, USA. Electronic address: adahbraun@yahoo.de.</nlm:affiliation></affiliation></author><author><name sortKey="Kostenuik, Paul J" sort="Kostenuik, Paul J" uniqKey="Kostenuik P" first="Paul J" last="Kostenuik">Paul J. Kostenuik</name><affiliation><nlm:affiliation>Department of Hematology/Oncology, Amgen Inc., Thousand Oaks, CA, USA. Electronic address: PKost@roadrunner.com.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26093811</idno><idno type="pmid">26093811</idno><idno type="doi">10.1016/j.ejca.2015.05.016</idno><idno type="wicri:Area/PubMed/Corpus">002962</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002962</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Hypocalcaemia in patients with metastatic bone disease treated with denosumab.</title><author><name sortKey="Body, Jean Jacques" sort="Body, Jean Jacques" uniqKey="Body J" first="Jean-Jacques" last="Body">Jean-Jacques Body</name><affiliation><nlm:affiliation>Department of Medicine, CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium. Electronic address: jean-jacques.body@chu-brugmann.be.</nlm:affiliation></affiliation></author><author><name sortKey="Bone, Henry G" sort="Bone, Henry G" uniqKey="Bone H" first="Henry G" last="Bone">Henry G. Bone</name><affiliation><nlm:affiliation>Michigan Bone and Mineral Clinic, Detroit, MI, USA. Electronic address: hgbone.md@att.net.</nlm:affiliation></affiliation></author><author><name sortKey="De Boer, Richard H" sort="De Boer, Richard H" uniqKey="De Boer R" first="Richard H" last="De Boer">Richard H. De Boer</name><affiliation><nlm:affiliation>Department of Medical Oncology, Royal Melbourne Hospital, Melbourne, VIC, Australia. Electronic address: richard.deboer@wh.org.au.</nlm:affiliation></affiliation></author><author><name sortKey="Stopeck, Alison" sort="Stopeck, Alison" uniqKey="Stopeck A" first="Alison" last="Stopeck">Alison Stopeck</name><affiliation><nlm:affiliation>Stony Brook Cancer Center, Stony Brook, NY, USA. Electronic address: Alison.Stopeck@stonybrookmedicine.edu.</nlm:affiliation></affiliation></author><author><name sortKey="Van Poznak, Catherine" sort="Van Poznak, Catherine" uniqKey="Van Poznak C" first="Catherine" last="Van Poznak">Catherine Van Poznak</name><affiliation><nlm:affiliation>Department of Medical Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA. Electronic address: cvanpoz@med.umich.edu.</nlm:affiliation></affiliation></author><author><name sortKey="Damiao, Ronaldo" sort="Damiao, Ronaldo" uniqKey="Damiao R" first="Ronaldo" last="Damião">Ronaldo Damião</name><affiliation><nlm:affiliation>Department of Urology, Hospital Universitario Pedro Ernesto, Rio de Janeiro, Brazil. Electronic address: damiao@email.com.</nlm:affiliation></affiliation></author><author><name sortKey="Fizazi, Karim" sort="Fizazi, Karim" uniqKey="Fizazi K" first="Karim" last="Fizazi">Karim Fizazi</name><affiliation><nlm:affiliation>Department of Medical Oncology, Institut Gustave Roussy, University of Paris Sud, Villejuif, France. Electronic address: Karim.FIZAZI@igr.fr.</nlm:affiliation></affiliation></author><author><name sortKey="Henry, David H" sort="Henry, David H" uniqKey="Henry D" first="David H" last="Henry">David H. Henry</name><affiliation><nlm:affiliation>Department of Medicine, Joan Karnell Cancer Center at Pennsylvania Hospital, Philadelphia, PA, USA. Electronic address: dhhenry@juno.com.</nlm:affiliation></affiliation></author><author><name sortKey="Ibrahim, Toni" sort="Ibrahim, Toni" uniqKey="Ibrahim T" first="Toni" last="Ibrahim">Toni Ibrahim</name><affiliation><nlm:affiliation>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS-Osteoncology and Rare Tumors Center, Meldola, Italy. Electronic address: toni.ibrahim@irst.emr.it.</nlm:affiliation></affiliation></author><author><name sortKey="Lipton, Allan" sort="Lipton, Allan" uniqKey="Lipton A" first="Allan" last="Lipton">Allan Lipton</name><affiliation><nlm:affiliation>Division of Oncology, Pennsylvania State University, Milton S. Hershey Medical Center, Hershey, PA, USA. Electronic address: alipton@hmc.psu.edu.</nlm:affiliation></affiliation></author><author><name sortKey="Saad, Fred" sort="Saad, Fred" uniqKey="Saad F" first="Fred" last="Saad">Fred Saad</name><affiliation><nlm:affiliation>Department of Surgery, University of Montreal Hospital Center, Montreal, QC, Canada. Electronic address: fredsaad@videotron.ca.</nlm:affiliation></affiliation></author><author><name sortKey="Shore, Neal" sort="Shore, Neal" uniqKey="Shore N" first="Neal" last="Shore">Neal Shore</name><affiliation><nlm:affiliation>Department of Urology, Carolina Urologic Research Center, Myrtle Beach, SC, USA. Electronic address: nshore@gsuro.com.</nlm:affiliation></affiliation></author><author><name sortKey="Takano, Toshimi" sort="Takano, Toshimi" uniqKey="Takano T" first="Toshimi" last="Takano">Toshimi Takano</name><affiliation><nlm:affiliation>Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan. Electronic address: takano@toranomon.gr.jp.</nlm:affiliation></affiliation></author><author><name sortKey="Shaywitz, Adam J" sort="Shaywitz, Adam J" uniqKey="Shaywitz A" first="Adam J" last="Shaywitz">Adam J. Shaywitz</name><affiliation><nlm:affiliation>Department of Hematology/Oncology, Amgen Inc., Thousand Oaks, CA, USA. Electronic address: ashaywitz@gmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Wang, Huei" sort="Wang, Huei" uniqKey="Wang H" first="Huei" last="Wang">Huei Wang</name><affiliation><nlm:affiliation>Department of Hematology/Oncology, Amgen Inc., Thousand Oaks, CA, USA. Electronic address: hueiw@amgen.com.</nlm:affiliation></affiliation></author><author><name sortKey="Bracco, Oswaldo L" sort="Bracco, Oswaldo L" uniqKey="Bracco O" first="Oswaldo L" last="Bracco">Oswaldo L. Bracco</name><affiliation><nlm:affiliation>Department of Hematology/Oncology, Amgen Inc., Thousand Oaks, CA, USA. Electronic address: ozzie.bracco@gmail.com.</nlm:affiliation></affiliation></author><author><name sortKey="Braun, Ada" sort="Braun, Ada" uniqKey="Braun A" first="Ada" last="Braun">Ada Braun</name><affiliation><nlm:affiliation>Department of Hematology/Oncology, Amgen Inc., Thousand Oaks, CA, USA. Electronic address: adahbraun@yahoo.de.</nlm:affiliation></affiliation></author><author><name sortKey="Kostenuik, Paul J" sort="Kostenuik, Paul J" uniqKey="Kostenuik P" first="Paul J" last="Kostenuik">Paul J. Kostenuik</name><affiliation><nlm:affiliation>Department of Hematology/Oncology, Amgen Inc., Thousand Oaks, CA, USA. Electronic address: PKost@roadrunner.com.</nlm:affiliation></affiliation></author></analytic><series><title level="j">European journal of cancer (Oxford, England : 1990)</title><idno type="eISSN">1879-0852</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic Agents (adverse effects)</term><term>Biomarkers (blood)</term><term>Bone Density Conservation Agents (adverse effects)</term><term>Bone Neoplasms (drug therapy)</term><term>Bone Neoplasms (secondary)</term><term>Calcium (blood)</term><term>Clinical Trials, Phase III as Topic</term><term>Denosumab (adverse effects)</term><term>Diphosphonates (adverse effects)</term><term>Humans</term><term>Hypocalcemia (blood)</term><term>Hypocalcemia (chemically induced)</term><term>Hypocalcemia (diagnosis)</term><term>Hypocalcemia (epidemiology)</term><term>Hypocalcemia (prevention & control)</term><term>Imidazoles (adverse effects)</term><term>Incidence</term><term>Retrospective Studies</term><term>Risk Assessment</term><term>Risk Factors</term><term>Severity of Illness Index</term><term>Time Factors</term><term>Treatment Outcome</term><term>Vitamin D Deficiency (complications)</term><term>Vitamin D Deficiency (diagnosis)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Agents</term><term>Bone Density Conservation Agents</term><term>Denosumab</term><term>Diphosphonates</term><term>Imidazoles</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Biomarkers</term><term>Calcium</term></keywords><keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Hypocalcemia</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Hypocalcemia</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Vitamin D Deficiency</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Hypocalcemia</term><term>Vitamin D Deficiency</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Bone Neoplasms</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Hypocalcemia</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Hypocalcemia</term></keywords><keywords scheme="MESH" qualifier="secondary" xml:lang="en"><term>Bone Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Clinical Trials, Phase III as Topic</term><term>Humans</term><term>Incidence</term><term>Retrospective Studies</term><term>Risk Assessment</term><term>Risk Factors</term><term>Severity of Illness Index</term><term>Time Factors</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This analysis was performed to further characterise treatment-emergent hypocalcaemia in patients with bone metastases receiving denosumab.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26093811</PMID><DateCreated><Year>2015</Year><Month>08</Month><Day>10</Day></DateCreated><DateCompleted><Year>2016</Year><Month>04</Month><Day>28</Day></DateCompleted><DateRevised><Year>2015</Year><Month>08</Month><Day>10</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0852</ISSN><JournalIssue CitedMedium="Internet"><Volume>51</Volume><Issue>13</Issue><PubDate><Year>2015</Year><Month>Sep</Month></PubDate></JournalIssue><Title>European journal of cancer (Oxford, England : 1990)</Title><ISOAbbreviation>Eur. J. Cancer</ISOAbbreviation></Journal><ArticleTitle>Hypocalcaemia in patients with metastatic bone disease treated with denosumab.</ArticleTitle><Pagination><MedlinePgn>1812-21</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejca.2015.05.016</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0959-8049(15)00447-5</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">This analysis was performed to further characterise treatment-emergent hypocalcaemia in patients with bone metastases receiving denosumab.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Laboratory abnormalities and adverse events of hypocalcaemia in patients with metastatic bone disease were analysed using data from three identically designed phase 3 trials of subcutaneous denosumab 120 mg (n = 2841) versus intravenous zoledronic acid 4 mg (n = 2836).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The overall incidence of laboratory events of hypocalcaemia grade ⩾ 2 was higher with denosumab (12.4%) than with zoledronic acid (5.3%). Hypocalcaemia events were primarily grade 2 in severity and usually occurred within the first 6 months of treatment. Patients who reported taking calcium and/or vitamin D supplements had a lower incidence of hypocalcaemia. Prostate cancer or small-cell lung cancer, reduced creatinine clearance and higher baseline bone turnover markers of urinary N-telopeptide of type I collagen (uNTx; > 50 versus ⩽ 50 nmol/mmol) and bone-specific alkaline phosphatase (BSAP; > 20.77 μg/L [median] versus ⩽ 20.77 μg/L) values were important risk factors for developing hypocalcaemia. The risk associated with increased baseline BSAP levels was greater among patients who had > 2 bone metastases at baseline versus those with ⩽ 2 bone metastases at baseline.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Hypocalcaemia was more frequent with denosumab versus zoledronic acid, consistent with denosumab's greater antiresorptive effect. Low serum calcium levels and potential vitamin D deficiency should be corrected before initiating treatment with a potent osteoclast inhibitor, and corrected serum calcium levels should be monitored during treatment. Adequate calcium and vitamin D intake appears to substantially reduce the risk of hypocalcaemia.</AbstractText><CopyrightInformation>Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Body</LastName><ForeName>Jean-Jacques</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Medicine, CHU Brugmann, Université Libre de Bruxelles, Brussels, Belgium. Electronic address: jean-jacques.body@chu-brugmann.be.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bone</LastName><ForeName>Henry G</ForeName><Initials>HG</Initials><AffiliationInfo><Affiliation>Michigan Bone and Mineral Clinic, Detroit, MI, USA. Electronic address: hgbone.md@att.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Boer</LastName><ForeName>Richard H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Royal Melbourne Hospital, Melbourne, VIC, Australia. Electronic address: richard.deboer@wh.org.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stopeck</LastName><ForeName>Alison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Stony Brook Cancer Center, Stony Brook, NY, USA. Electronic address: Alison.Stopeck@stonybrookmedicine.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Poznak</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA. Electronic address: cvanpoz@med.umich.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Damião</LastName><ForeName>Ronaldo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Urology, Hospital Universitario Pedro Ernesto, Rio de Janeiro, Brazil. Electronic address: damiao@email.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fizazi</LastName><ForeName>Karim</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Institut Gustave Roussy, University of Paris Sud, Villejuif, France. Electronic address: Karim.FIZAZI@igr.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henry</LastName><ForeName>David H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Department of Medicine, Joan Karnell Cancer Center at Pennsylvania Hospital, Philadelphia, PA, USA. Electronic address: dhhenry@juno.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ibrahim</LastName><ForeName>Toni</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS-Osteoncology and Rare Tumors Center, Meldola, Italy. Electronic address: toni.ibrahim@irst.emr.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lipton</LastName><ForeName>Allan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Oncology, Pennsylvania State University, Milton S. Hershey Medical Center, Hershey, PA, USA. Electronic address: alipton@hmc.psu.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saad</LastName><ForeName>Fred</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Montreal Hospital Center, Montreal, QC, Canada. Electronic address: fredsaad@videotron.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shore</LastName><ForeName>Neal</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Urology, Carolina Urologic Research Center, Myrtle Beach, SC, USA. Electronic address: nshore@gsuro.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takano</LastName><ForeName>Toshimi</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan. Electronic address: takano@toranomon.gr.jp.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaywitz</LastName><ForeName>Adam J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Hematology/Oncology, Amgen Inc., Thousand Oaks, CA, USA. Electronic address: ashaywitz@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Huei</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Hematology/Oncology, Amgen Inc., Thousand Oaks, CA, USA. Electronic address: hueiw@amgen.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bracco</LastName><ForeName>Oswaldo L</ForeName><Initials>OL</Initials><AffiliationInfo><Affiliation>Department of Hematology/Oncology, Amgen Inc., Thousand Oaks, CA, USA. Electronic address: ozzie.bracco@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Braun</LastName><ForeName>Ada</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Hematology/Oncology, Amgen Inc., Thousand Oaks, CA, USA. Electronic address: adahbraun@yahoo.de.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kostenuik</LastName><ForeName>Paul J</ForeName><Initials>PJ</Initials><AffiliationInfo><Affiliation>Department of Hematology/Oncology, Amgen Inc., Thousand Oaks, CA, USA. Electronic address: PKost@roadrunner.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00321464</AccessionNumber><AccessionNumber>NCT00321620</AccessionNumber><AccessionNumber>NCT00330759</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Cancer</MedlineTA><NlmUniqueID>9005373</NlmUniqueID><ISSNLinking>0959-8049</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050071">Bone Density Conservation Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004164">Diphosphonates</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007093">Imidazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>4EQZ6YO2HI</RegistryNumber><NameOfSubstance UI="D000069448">Denosumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>6XC1PAD3KF</RegistryNumber><NameOfSubstance UI="C088658">zoledronic acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>SY7Q814VUP</RegistryNumber><NameOfSubstance UI="D002118">Calcium</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="N">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050071" MajorTopicYN="N">Bone Density Conservation Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001859" MajorTopicYN="N">Bone Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000556" MajorTopicYN="Y">secondary</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002118" MajorTopicYN="N">Calcium</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017326" MajorTopicYN="N">Clinical Trials, Phase III as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069448" MajorTopicYN="N">Denosumab</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004164" MajorTopicYN="N">Diphosphonates</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006996" MajorTopicYN="N">Hypocalcemia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000139" MajorTopicYN="Y">chemically induced</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007093" MajorTopicYN="N">Imidazoles</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014808" MajorTopicYN="N">Vitamin D Deficiency</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bone metastasis</Keyword><Keyword MajorTopicYN="N">Denosumab</Keyword><Keyword MajorTopicYN="N">Hypocalcaemia</Keyword><Keyword MajorTopicYN="N">Risk factors</Keyword><Keyword MajorTopicYN="N">Zoledronic acid</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>03</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>05</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>05</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26093811</ArticleId><ArticleId IdType="pii">S0959-8049(15)00447-5</ArticleId><ArticleId IdType="doi">10.1016/j.ejca.2015.05.016</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002962 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 002962 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:26093811
|texte= Hypocalcaemia in patients with metastatic bone disease treated with denosumab.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:26093811" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |